Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2028 revenue reaching $3.28T — +2.9% growth in a single year.
What Moves the Stock
01Japanese government drug pricing revisions (biennial NHI price cuts averaging 2-4% impact distributor margins and inventory valuation)
02Prescription drug volume growth driven by aging demographics (Japan's 65+ population now 29% and rising, driving chronic disease medication demand)
03Market share shifts among top 4 distributors (Alfresa, Medipal, Suzuken, Toho) through hospital contract wins or pharmacy network expansion
04Generic drug penetration rates (currently ~80% by volume in Japan, affecting mix and margin profile)
05M&A activity consolidating fragmented regional distributors or vertical integration into pharmacy retail
06Pharmaceutical wholesale distribution (~85% of revenue): bulk procurement from manufacturers, warehousing, and delivery to retail pharmacies and hospitals
07Medical device and equipment distribution (~12% of revenue): surgical instruments, diagnostic equipment, and consumables to healthcare facilities
08Dispensing pharmacy operations and healthcare services (~3% of revenue): retail pharmacy chains and ancillary healthcare logistics
value - Alfresa trades at 0.2x P/S and 0.9x P/B, attracting value investors seeking defensive healthcare exposure at depressed multiples.
Moderate sensitivity through working capital financing costs.
Watch on earnings: Japanese pharmaceutical market volume growth (total prescriptions dispensed, tracked by Ministry of Health), NHI drug price revision announcements (biennial policy changes typically announced April, implemented following fiscal year), Alfresa's market share in hospital vs. pharmacy channels (hospital contracts are larger but lower margin; pharmacy is fragmented but higher margin).
One Sentence Summary:
Alfresa: the story is balanced — japanese government drug pricing revisions (biennial nhi price cuts averaging 2-4% impact distributor margins and inventory valuation).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
